|Mr. John Dawson||CEO & Exec. Director||N/A||N/A||57|
|Mr. Peter Nolan||Chief Bus. Officer & Exec. Director||N/A||N/A||64|
|Mr. Timothy William Watts||Exec. Officer||N/A||N/A||59|
|Mr. Stuart Paynter||CFO & Director||N/A||N/A||N/A|
|Dr. James Miskin Ph.D.||Chief Technology Officer||N/A||N/A||N/A|
Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes. The company's products under development include OXB-102 that has completed Phase I/II trial for the treatment of Parkinson's disease; OXB-202, which is in a Phase I/IIa trial preparation for the prevention of corneal graft rejection; OXB-301, a cancer vaccine which is in a Phase I/II trial; and OXB-302, which is based on an autologous T-cell that is engineered using a lentiviral vector to express a chimeric antigen receptor targeting multiple cancers, as well as OXB-201 that is in Phase I/II trial for the treatment of ?wet' age-related macular degeneration and diabetic retinopathy. It is also developing SAR 422459 that is in a Phase II trial for the treatment of Stargardt disease; and SAR 421869, a gene-based therapy that is in Phase I/II trial for the treatment of Usher syndrome 1B. The company has partnerships with Sanofi, GlaxoSmithKline, Novartis, Green Cross LabCell, and Immune Design Corp. Oxford BioMedica plc was founded in 1995 and is headquartered in Oxford, the United Kingdom.
Oxford BioMedica PLC’s ISS Governance QualityScore as of February 1, 2018 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 1; Compensation: 5.